AbCellera Biologics Inc. Common Shares (ABCL)
Stock · NASDAQ · Health Care
$11.8as of 10/16/2026
Price chart
Active signals
ABCL Signal Track Record
How signals performed across all stocks →What ABCL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -0.1% | 50% | September 29, 2026 |
| Bollinger Band Breakout | 23 | -2.4% | 43% | September 17, 2026 |
| Bollinger Band Breakdown | 19 | -5.7% | 47% | February 4, 2026 |
| 200-Day Moving Average TouchActive now | 16 | -0.3% | 44% | May 18, 2026 |
| Any 20-session window (baseline) | 0.0% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ABCL
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 562
- Website
- www.abcellera.com/
Fundamentals
- 1-day range
- $11.72$12.68
- Market cap
- $1.92B
- P/E (trailing)
- —
- P/E (forward)
- -15.48
- EPS (trailing)
- $-0.54
- Dividend yield
- —
- Beta
- 1.55
- Avg. volume
- 6.64M
How AbCellera Biologics Inc. Common Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 24, 2026 · via SEC EDGAR / Finnhub
Forecasts
11 analyst ratings
AbCellera Biologics Inc. Common Shares Competitors
Chosen by industry and closest market cap.
- ABCLAbCellera Biologics Inc. Common Shares$11.8▼ 6.94%Market cap $1.92BP/E —$2.75$15.02
- OCULOcular Therapeutix Inc. Common Stock$6.87▼ 6.91%Market cap $1.92BP/E —$6.23$16.44
- AGIOAgios Pharmaceuticals Inc. Common Stock$31.32▼ 3.09%Market cap $1.91BP/E —$22.24$46
- NAMSWNewAmsterdam Pharma Company N.V. Warrant$9▼ 17.81%Market cap $1.87BP/E —$9.79$30.45
- ANIPANI Pharmaceuticals Inc.$72.29▲ 0.01%Market cap $1.86BP/E 15.16$69.58$97
- DMRADamora Therapeutics Inc. Ordinary Shares$18.44▼ 1.60%Market cap $1.84BP/E —$16.5$34.89
- NBTXNanobiotix S.A. American Depositary Shares$21.3▼ 4.18%Market cap $1.83BP/E —$13.1$47.66
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ABCL AbCellera Biologics Inc. Common Shares | $1.92B | — | $11.8 | ▼ 6.94% | $2.75$15.02 |
| OCUL Ocular Therapeutix Inc. Common Stock | $1.92B | — | $6.87 | ▼ 6.91% | $6.23$16.44 |
| AGIO Agios Pharmaceuticals Inc. Common Stock | $1.91B | — | $31.32 | ▼ 3.09% | $22.24$46 |
| NAMSW NewAmsterdam Pharma Company N.V. Warrant | $1.87B | — | $9 | ▼ 17.81% | $9.79$30.45 |
| ANIP ANI Pharmaceuticals Inc. | $1.86B | 15.16 | $72.29 | ▲ 0.01% | $69.58$97 |
| DMRA Damora Therapeutics Inc. Ordinary Shares | $1.84B | — | $18.44 | ▼ 1.60% | $16.5$34.89 |
| NBTX Nanobiotix S.A. American Depositary Shares | $1.83B | — | $21.3 | ▼ 4.18% | $13.1$47.66 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- UBS Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $18benzinga · 10/12/2026
- AbCellera Biologics (ABCL) Could Be 27% Undervalued As ABCL635 Data Draws FocusYahoo · 10/9/2026
- What Could Go Wrong With Recursion Pharmaceuticals Stock?Yahoo · 10/8/2026
- AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual MeetingYahoo · 10/8/2026
- AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026Yahoo · 10/1/2026
- AI Drug Discovery Forecasts Vary Widely as Sector Shifts to DeploymentYahoo · 10/1/2026
- Vasomotor Symptoms Market Poised for Growth Through 2036, Driven by Rising Adoption of Hormonal and Non-Hormonal Therapies | DelveInsightYahoo · 9/30/2026
- Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?Yahoo · 9/30/2026
- JP Morgan Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $17Benzinga · 9/29/2026
Insider Activity
Insider Actions →- Michael R. Hayden · August 24, 2026 · Buy53.6K @ $10.64
- John S. Montalbano · August 18, 2026 · Buy10.0K @ $11.03
- Andrew Booth · August 14, 2026 · Buy37.2K @ $10.32
- Michael R. Hayden · August 12, 2026 · Buy46.4K @ $10.37
- Michael R. Hayden · August 11, 2026 · Gift50.0K
- Victor Sandor · July 1, 2026 · Grant152.2K
- Seely Lynn · July 1, 2026 · Grant152.2K
- John S. Montalbano · June 11, 2026 · Grant111.7K
- Quake Stephen · June 11, 2026 · Grant111.7K
- Michael R. Hayden · June 11, 2026 · Grant111.7K
- Andrew Booth · June 3, 2026 · Option Exercise250.0K @ $0.19
- John S. Montalbano · May 14, 2026 · Buy20.0K @ $4.77
Institutional Ownership
March 31, 2026
- Total shares held
- 129.17M
- Total value held
- $446.06M
- Institutional holders
- 135
- Unknown30.28M
- Unknown13.36M
- Unknown10.56M
- Unknown9.56M
- Unknown7.58M
- Unknown5.48M
- Unknown4.21M
- Unknown4.11M
- Unknown4.04M
- Unknown4.02M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ABCL: UBS Coverage, ABCL635 Data, and Phase 1/2 Results
UBS has begun coverage of AbCellera, setting a price target of $18. The company’s ABCL635 antibody is drawing attention after a recent analysis suggesting it may be undervalued by 27%. AbCellera will present Phase 1/2 data for ABCL635 at the TMS 2026 Annual Meeting, providing further insight into its clinical progress. These developments come as the broader biotech sector sees strong earnings from peers such as Nurix Therapeutics.
ABCL: UBS Coverage, ABCL635 Data, and Phase 1/2 Results. UBS has begun coverage of AbCellera, setting a price target of $18. The company’s ABCL635 antibody is drawing attention after a recent analysis suggesting it may be undervalued by 27%. AbCellera will present Phase 1/2 data for ABCL635 at the TMS 2026 Annual Meeting, providing further insight into its clinical progress. These developments come as the broader biotech sector sees strong earnings from peers such as Nurix Therapeutics.